Advertisement


Howard M. Sandler, MD, on Prostate Cancer Highlights: An Expert Perspective

2021 ASTRO Annual Meeting

Advertisement

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses whether hypofractionation can be safely employed in the post-prostatectomy setting and the role of short-term hormone therapy in the management of intermediate-risk prostate cancer with radiotherapy.



Related Videos

Prostate Cancer

Benjamin Movsas, MD, on Prostate Cancer: Patient-Reported Outcomes on Radiotherapy and Androgen Suppression

Benjamin Movsas, MD, of the Henry Ford Cancer Center, discusses results from the NRG Oncology/RTOG 0815 study, which explored dose-escalated radiotherapy alone or in combination with short-term hormonal therapy for patients with intermediate-risk prostate cancer. In addition to clinical outcomes, Dr. Movsas discusses patient-reported results in the study that may help patients make informed decisions when choosing between these treatment options (Abstract 4).

Solid Tumors

Robert A. Olson, MD, on Oligometastases: New Data on Stereotactic Ablative Radiotherapy

Robert A. Olson, MD, of the University of British Columbia, discusses phase II findings from the SABR-5 trial on stereotactic ablative radiotherapy for up to five oligometastases. Although toxicity of liver and adrenal metastases warrants caution, the trial seemed to show that this type of radiation treatment is relatively safe and should be studied further, given the long overall survival in this patient population (Abstract 6).

Breast Cancer
Lung Cancer

C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers

C. Jillian Tsai, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses results from the first randomized trial of stereotactic body radiation therapy (SBRT) to treat oligoprogressive, metastatic lung and breast cancers. The standard of care for patients with these types of tumors is to switch to a different systemic treatment. Adding local therapy such as SBRT may help treat drug-resistant lesions (Abstract LBA3).

 

Head and Neck Cancer

Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

Daniel J. Ma, MD, of the Mayo Clinic Alix School of Medicine, discusses results from a phase III study of patients with HPV-associated oropharyngeal squamous cell carcinoma. Comparing a 2-week course of de-escalated adjuvant radiation therapy with the standard 6-week course, investigators found that the shorter treatment appeared to have less toxicity, higher quality of life, and similar disease control as the longer standard-of-care treatment (Abstract LBA1).

Prostate Cancer

Mark K. Buyyounouski, MD, MS, on Prostate Cancer: Hypofractionated vs Conventional Radiotherapy After Surgery

Mark K. Buyyounouski, MD, MS, of Stanford University, discusses phase III results from the NRG Oncology GU003 trial, which showed that, post-prostatectomy, using fewer—but higher—doses of radiation does not appear to increase long-term side effects or reduce quality of life when compared with conventional radiation treatment (Abstract 3).

Advertisement

Advertisement




Advertisement